 CAMBRIDGE, Mass. , Oct. 5, 2022 PRNewswire -- Leap Therapeutics, Inc. Nasdaq: LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from Part B of the DisTinGuish Study evaluating DKN-01 in combination with tislelizumab, BeiGenes anti-PD-1 antibody, in second-line gastroesophageal junctiongastric GEJG cancer patients whose tumors express high levels of DKK1 DKK1-high at the Society of Immunotherapy for Cancer SITC 37th Annual Meeting being held in Boston, MA on November 8-12, 2022. 